Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 9;12:1536. doi: 10.1038/s41467-021-21784-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a Two-sided Pearson’s correlation between the effects (i.e., normalized growth rates) of Kdm1a inhibitor SP2509 (at 1 μM), Jmj-KDM inhibitor JIB-04 (at 200 nM), BET inhibitors OTX015 (at 200 nM), and I-BET762 (at 1 μM), used individually or in combination with vemurafenib (at 100 nM) plus trametinib (at 10 nM) and evaluated across 16 BRAF-mutant melanoma cell lines. b Log₂-normalized changes in live cell count following exposure of seven selected melanoma cell lines and non-transformed primary melanocytes to different drugs at indicated doses for a period of 5 days. MMACSF, WM115, and WM902B cell lines represent cell lines that exhibit high sensitivity to the combination of JIB-04 or BET inhibitors with Braf/Mek inhibitors, while being resistant to SP2509. A2058, A375, and A375(NRAS^Q61K) represent cell lines that are highly sensitive to SP2509. HS294T cells show partial sensitivity to either of the compounds. Data are presented as the average of n = 6 biologically independent samples (in case of MMACSF, WM115, HS294T, A2058, A375, A375(NRAS^Q61K) and primary melanocytes), or the average of n = 2 biologically independent samples (in case of WM902B). c Measurements of normalized growth rate (left) and deviation from Bliss independence (DBI) values computed across diverse epigenetic inhibitor treatments in combination with vemurafenib plus trametinib. Experimental conditions and the analysis approach are the same as in Fig. 3. d Log₂-normalized changes in live cell count following exposure of three selected melanoma cell lines to different drugs at indicated doses for a period of 20 days. Data are presented as mean values ± s.d. across n = 4 biologically independent samples. Source data are provided as a Source data file.